APO-LOXAPINE 10 MG
LOXAPINE (LOXAPINE SUCCINATE) : 10 MG · DIN 02237652 · APOTEX INC
Health Canada status: APPROVED
What is APO-LOXAPINE?
APO-LOXAPINE 10 MG contains LOXAPINE (LOXAPINE SUCCINATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02237652, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 09-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-LOXAPINE used for?
APO-LOXAPINE (loxapine succinate tablets) is indicated in the management of the manifestations of schizophrenia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02237652 |
|---|---|
| Brand name | APO-LOXAPINE |
| Generic / active ingredient | LOXAPINE (LOXAPINE SUCCINATE) : 10 MG |
| Manufacturer | APOTEX INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AH01 LOXAPINE |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 09-Feb-2022 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02237652 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2237652 |
| Brand name | APO-LOXAPINE |
| Active ingredient / INN | LOXAPINE (LOXAPINE SUCCINATE) : 10 MG |
| ATC code | N05AH01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
How is it stored and handled?
null
How is it supplied?
5 mg: Available in bottles of 100, 250, 500 and 1000 tablets. 10 mg: Available in bottles of 100, 250, 500 and 1000 tablets. 25 mg: Available in bottles of 100, 250, 500 and 1000 tablets. 50 mg: Available in bottles of 100, 250, 500 and 1000 tablets.
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | 5 mg: Available in bottles of 100, 250, 500 and 1000 tablets. 10 mg: Available in bottles of 100, 250, 500 and 1000 tablets. 25 mg: Available in bottles of 100, 250, 500 and 1000 tablets. 50 mg: Available in bottles of 100, 250, 500 and 1000 tablets. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code N05AH01 LOXAPINE. 4 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LOXAPAC IM | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02169991 |
| XYLAC | 10 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230838 |
| XYLAC | 2.5 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02242868 |
| XYLAC | 25 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230839 |
| APO-LOXAPINE | 25 MG | TABLET | APOTEX INC | APPROVED | DIN 02237653 |
| APO-LOXAPINE | 5 MG | TABLET | APOTEX INC | APPROVED | DIN 02237651 |
| APO-LOXAPINE | 50 MG | TABLET | APOTEX INC | APPROVED | DIN 02237654 |
| DOM-LOXAPINE TABLETS 10MG | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239919 |
| DOM-LOXAPINE TABLETS 25MG | 25 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239920 |
| DOM-LOXAPINE TABLETS 50MG | 50 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239921 |
How much does LOXAPINE cost around the world?
LOXAPINE is listed on 2 national price registers Nexara tracks, across 15 pack listings published on 2 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 4 | 14 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.